The head of the government’s effort to develop a vaccine against Kovid-19 says he expects the efficacy rate of this vaccination to be in the “90%” range – but not enough vaccines are available to all Americans by the end of next year Can. .
“I think it will be a very effective vaccine. This is my prediction,” said Monsef Saloi, chief advisor at Operation Tana Speed. “Based on my experience and the biology of this virus, my personal opinion, I think this vaccine is going to be highly effective. I wouldn’t be surprised if it’s in the 90%. [range]. ”
Saloi, an immunologist, previously led the vaccine program at GlaxoSmithKline, where he led the development of five major novel vaccines.
He said that by mid-2021 there would be “ideally” enough vaccines for all Americans, but possibly not until the end of 2021.
Saloi spoke with CNN senior medical correspondent Elizabeth Cohen on Thursday while visiting a Kovid-19 vaccine clinical trial site in Savannah, Georgia. It was his first television interview since joining Operation Tana Gati in May.
When will everyone be vaccinated?
In June, Drs. Anthony Fauci gave Cohen a less optimistic forecast for the effectiveness of the Kovid-19 vaccine.
“The best thing we’ve done so far is measles, which is 97 to 98 percent effective,” said Fauci, director of the National Institute of Allergy and Infectious Diseases. “It will be wonderful if we get there. I don’t think we will. I’ll compromise for that.” [a] 70, 75% effective vaccine. ”
The US Food and Drug Administration has set an even lower standard for the Kovid-19 vaccine, stating in its guidelines that efficacy rates should be “at least 50%.”
Vaccines have different effectiveness rates. According to the American Centers for Disease Control and Prevention, a full round of polio vaccine is 99% to 100% effective; Complete immunization is 80–90% effective against diphtheria, tetanus, and pertussis, while the flu shot is 40–60% effective.
Saloi said that with the Kovid-19 vaccine, “it is possible that we will need a booster after initial vaccination every year or every two years or every three years”. “
Saloui said he expects there will be “a few million doses” of the vaccine in December of this year or January of next year, and that they will move to high-risk individuals because “we won’t have a dose for the entire population of America one day.” . “
High-risk individuals include the elderly and underlying health conditions such as high blood pressure, diabetes, and heart disease.
Saloi said he is “optimistic” there will be vaccines for all Americans by the end of 2021, but ideally by mid-2021.
“That’s our purpose,” he said.
Vaccination is growing at a record pace
Operation Warp Speed is financing eight vaccines, Slaoui said.
Five of them are already in Phase 3 clinical trials or will begin by the end of September, he said. A Phase 3 trial is the final round of trials before a vaccine goes past the regulators, and can be planted on the market. The Kovid-19 vaccine phase 3 trials will each include 30,000 study subjects.
“They are all different vaccines. They are really going very fast,” Saloi said, noting that the virus was identified just six months ago. “I’ve been doing this for 30 years, and the fastest thing I remember was that the discovery went from phase three trials in four years.”
The vaccines made by Modern and Pfizer are in Phase 3 in the United States, and a vaccine by AstraZeneca is in Phase 3 trials in the United Kingdom, Brazil and South Africa. Phase 3 trials for that vaccine are expected to begin in the US in August.
Phase 3 trials for vaccines made by two other companies – Johnson & Johnson and Novavax – are scheduled to begin in September.
Saloi has not named the other three vaccines that will receive funds at Operation Tana Pace.
Video: Here’s what Fauci thinks of the latest vaccine test (CNN)